International Journal of Antimicrobial Agents

IFC - Aim/Scope/Editorial Board
pp. CO2-CO2(1)

Empirical antifungal therapy
pp. 105-112(8)
Author: Klastersky J.

Oxazolidinones: activity, mode of action, and mechanism of resistance
pp. 113-119(7)
Authors: Bozdogan B.; Appelbaum P.C.

Antibiotic therapy for severe bacterial infections: correlation between the inhibitory quotient and outcome
pp. 120-128(9)
Authors: Spanu T.; Santangelo R.; Andreotti F.; Cascio G.L.; Velardi G.; Fadda G.

Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis
pp. 129-137(9)
Authors: Starakis I.; Gogos C.A.; Bassaris H.

Telephonic back-up improves antibiotic compliance in acute tonsillitis/pharyngitis
pp. 138-143(6)
Authors: Urien A.M.; Guillen V.F.G.; Beltran D.O.; Pinzotas C.L.-Q.; Perez E.R.; Arocena M.O.; Sanchez J.M.

Pharmacokinetic interactions of ceftazidime, imipenem and aztreonam with amikacin in healthy volunteers
pp. 144-149(6)
Authors: Adamis G.; Papaioannou M.G.; Giamarellos-Bourboulis E.J.; Gargalianos P.; Kosmidis J.; Giamarellou H.

Immunomodulating effect of antimicrobial agents on cytokine production by human polymorphonuclear neutrophils
pp. 150-154(5)
Authors: Reato G.; Cuffini A.M.; Tullio V.; Mandras N.; Roana J.; Banche G.; Foa R.; Carlone N.A.

Bacteraemia in Europe-antimicrobial susceptibility data from the MYSTIC surveillance programme
pp. 155-163(9)
Authors: Unal S.; Masterton R.; Goossens H.

Conflicting interpretations of the prevalence of mutations associated with drug resistance in antiviral naive HIV-1 patients with acute and chronic infection
pp. 164-168(5)
Authors: Re M.C.; Monari P.; Bon I.; Borderi M.; Chiodo F.; HIV-1 Emilia Romagna Infectious Disease Study Group

Measurement of the antibiotic susceptibility of Coxiella burnetii using real time PCR
pp. 169-174(6)
Authors: Boulos A.; Rolain J.-M.; Maurin M.; Raoult D.

Dissemination of CTX-M type -lactamases in Enterobacteriaceae isolates in the People's Republic of China
pp. 175-180(6)
Authors: Munday C.J.; Xiong J.; Li C.; Shen D.; Hawkey P.M.

In vitro activity of gemifloxacin and contemporary oral antimicrobial agents against 27,247 Gram-positive and Gram-negative aerobic isolates: a global surveillance study
pp. 181-196(16)
Authors: Bouchillon S.K.; Hoban D.J.; Johnson J.L.; Johnson B.M.; Butler D.L.; Saunders K.A.; Miller L.A.; Poupard J.A.

Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide
pp. 197-199(3)
Authors: Jones R.N.; Streit J.M.; Fritsche T.R.

Emergence of resistance to chloramphenicol among vancomycin-resistant enterococcal (VRE) bloodstream isolates
pp. 200-203(4)
Authors: Lautenbach E.; Gould C.V.; LaRosa L.A.; Marr A.M.; Nachamkin I.; Bilker W.B.; Fishman N.O.

Efficacy of oral levofloxacin and dirithromycin alone and in combination with rifampicin in the treatment of experimental murine Brucella abortus infection
pp. 204-207(4)
Authors: Arda B.; Tuncel M.; Yaimazhan T.; Gokengin D.; Gurel O.

Recording zone sizes-a rare phenomenon in microbiology laboratories?
pp. 208-208(1)
Author: Shah P.M.